Driving Laws and Prescribed Cannabis: South Australia

Forty-eight hours. That is roughly the window most pharmacists quote when patients ask how long prescribed cannabis might remain detectable in saliva. The problem is that South Australia's drug-driving law does not care about that window, or about whether your product was legally prescribed. If a roadside swab returns a positive reading for tetrahydrocannabinol (THC), you are in breach , full stop.

I've spent enough time reading the Poisons Standard and state traffic legislation to say, without hesitation, that this is the single most misunderstood intersection between prescribed cannabis access and everyday Australian life. It comes up constantly in the policy circles I follow out of Canberra, and it deserves a clear, factual walkthrough rather than the vague reassurances that sometimes circulate online.

The SA drug-driving framework in plain terms

South Australia's drug-driving provisions sit within the Road Traffic Act 1961 (SA) and the Motor Vehicles Act 1959 (SA), enforced through the Road Traffic (Miscellaneous) Regulations 2014. The offence is straightforward: it is unlawful to drive or attempt to drive a motor vehicle while a prescribed drug , which includes THC , is present in your oral fluid, blood, or urine. There is no threshold under the oral fluid test. Detectable presence is the standard.

South Australia Police (SAPOL) conduct random roadside Drug Recognition Evaluations using oral fluid testing. A preliminary positive is followed by a second oral fluid sample that is sent to Forensic Science SA for laboratory confirmation. A confirmed positive result means you face a first-offence disqualification period and a fine, with escalating penalties for repeat offences. A blood sample may also be required in some circumstances, particularly following a crash or where a driver is suspected of impairment.

The critical legal point: a valid prescription is not a defence to the presence offence. South Australia does not currently have a "lawful prescription" exemption in its drug-driving legislation for the presence component of the offence. This is distinct from the impairment offence, which is a separate provision and exists regardless of the substance involved.

How this differs from other Australian jurisdictions

It is worth pausing here, because Australian state and territory drug-driving laws are not uniform, and that lack of uniformity causes genuine confusion for patients who move interstate or who read information written for a different jurisdiction.

Victoria, for example, also applies a zero-tolerance presence standard with no prescription defence; following a 2024 review, Victoria still had not legislated a medicinal cannabis exemption at the time of writing. Queensland operates similarly. The Australian Capital Territory, where I'm based, has the same presence-based structure. Western Australia introduced a prescribed cannabis medicinal use defence in 2023 under amendments to the Road Traffic Administration Act 2008 (WA), though that defence carries its own conditions around proof of prescription and non-impairment.

South Australia has not followed Western Australia's lead yet. Whether it will is genuinely unclear, the SA Government has flagged awareness of the issue, but no amending legislation had passed as of mid-2025. Laws in this area change, and patients should check directly with the SA Government's current drug-driving information before drawing conclusions from this or any other summary.

THC, CBD, and what the oral fluid test actually detects

Roadside oral fluid tests in South Australia screen for THC specifically, not for cannabidiol (CBD). This matters, because prescribed cannabis products in Australia span a spectrum. Some carry meaningful THC concentrations and are scheduled as Schedule 8 controlled drugs under the Poisons Standard. Others are predominantly CBD-based products scheduled under Schedule 4, with THC content low enough that the oral fluid test may not return a positive, though I would be very cautious about framing that as a guarantee, because individual oral fluid THC thresholds and metabolite persistence vary with product formulation, dose, frequency of use, and individual pharmacokinetics.

The short version is this: if your prescribed product contains any appreciable THC, you should assume the roadside test may detect it and act accordingly. That is the only safe position under current SA law.

Products described as full-spectrum will contain THC alongside other cannabinoids by definition. Broad-spectrum formulations aim to reduce THC while retaining other phytoconstituents, and isolate products contain a single purified compound; but none of these categories map neatly onto "will or won't trigger a roadside test" without knowing the actual THC content and the individual's elimination rate. There is genuine pharmacokinetic variability here that the law does not account for.

How prescribed cannabis is accessed in SA

To understand the driving issue in context, it helps to understand how these products reach patients. Prescribed cannabis in Australia is not available over the counter. It enters the market through federal access pathways, primarily the TGA's Special Access Scheme (SAS-B) and the Authorised Prescriber pathway, and must be listed on or approved through the Australian Register of Therapeutic Goods (ARTG), or accessed via the SAS with appropriate approval.

A South Australian patient with a valid prescription is entirely compliant with Commonwealth and state health law when they obtain and use their product. But the moment they get behind the wheel after using a THC-containing product, they are in a separate legal territory governed by state traffic law, and the prescription provides no protection under that framework.

This is not a critique of the prescription system; the TGA's access architecture is reasonable and relatively accessible by international standards. It is a structural policy problem: two arms of law, federal and state, that have not yet been reconciled from the patient's perspective. Honestly, I think South Australia is overdue for the kind of reform Western Australia has already attempted, but I also understand that legislators want more detection technology and research before they move. That's a fair enough position, even if it leaves patients in a difficult spot right now.

Practical implications for patients in SA

None of this constitutes legal advice, and patients should speak directly with their prescribing doctor and, if needed, a legal professional. But there are a few factual points worth understanding:

• THC can remain detectable in oral fluid for anywhere from a few hours to several days, depending on frequency of use, dose, formulation, and individual metabolism. There is no single safe window that applies universally.
• Blood THC testing, which may occur after a crash or in some enforcement contexts, operates on different timelines and different detection windows to oral fluid.
• There is no current legal mechanism in SA that exempts a prescribed cannabis patient from the presence offence.
• Impairment, regardless of cause, is a separate and additional offence. Driving impaired, by any substance including legally prescribed medication, is unlawful everywhere in Australia.

A prescribing doctor or cannabis nurse practitioner should be discussing driving implications with patients at the point of initiation. If that conversation hasn't happened, patients are well within their rights to raise it directly. The question isn't embarrassing or unusual; it's practical and important.

The detection technology question

One thread that comes up regularly in policy discussions is whether roadside oral fluid tests accurately reflect impairment. The short answer is: they don't claim to. They detect presence. There is ongoing scientific debate about the relationship between oral fluid THC concentration and impairment, and a number of jurisdictions internationally have moved to concentration-based thresholds rather than simple presence detection. Australia, including SA, has not yet gone down that path at scale.

Research published through the Australasian College of Road Safety and work cited by the TGA's medicinal cannabis guidance documents both acknowledge the gap between detection and impairment for regular cannabis users. Whether that gap should translate to a legislative exemption, a threshold-based standard, or something else entirely is a live policy question, one I'll be watching from the saddle on my Sunday road rides for a while yet, I suspect. (Between the long climbs out past the Barton Highway corridor and checking in on Trevor the sourdough starter, policy reading does fill the gaps.)

For now, the legal position in South Australia remains unchanged: THC present in your system while driving is an offence, regardless of how it got there.

Sources

• Drug driving, SA.gov.au, South Australian Government
• Medicinal cannabis guidance documents; Therapeutic Goods Administration (TGA)
• Road Traffic Act 1961 (SA), SA Legislation
• Cannabis and driving: a review of the literature, National Library of Medicine (NCBI)

, Marcus Hale, Regulatory researcher; TGA & access law

]]>